All Drug Responsive Sequences
All
Approved drugs
Short
Long
Human
Non-Human
Small proportional length
All drug-responsive elements which respond to a Guide to PHARMACOLOGY ligand ().
ID | Target | Species | Ligand | Length | Proportional length |
---|---|---|---|---|---|
1190 | M2 receptor | Human | [3H]QNB | 303 | 64.7% |
1460 | A2A receptor | Human | CGS 21680 | 195 | 59.7% |
1467 | A2A receptor | Human | NECA | 195 | 59.7% |
1469 | A2A receptor | Human | [3H]CGS 21680 | 195 | 59.7% |
1470 | A2A receptor | Human | [3H]NECA | 195 | 59.7% |
1490 | A2A receptor | Human | xanthine amine congener | 194 | 58.7% |
1491 | A2A receptor | Human | ZM-241385 | 250 | 51.0% |
1494 | A2A receptor | Human | [3H]XAC | 194 | 58.7% |
1495 | A2A receptor | Human | caffeine | 107 | 32.2% |
1862 | β2-adrenoceptor | Human | (-)-adrenaline | 176 | 37.3% |
1873 | β2-adrenoceptor | Human | ICI 118551 | 332 | 67.6% |
1879 | β2-adrenoceptor | Human | alprenolol | 336 | 68.4% |
1888 | β2-adrenoceptor | Human | timolol | 335 | 68.2% |
2181 | CaS receptor | Human | Ca2+ | 8 | 1.1% |
2310 | CCR5 | Human | [3H]maraviroc | 298 | 71.7% |
2313 | CCR5 | Human | maraviroc | 298 | 71.7% |
2478 | CRF2 receptor | Human | urocortin 1 | 424 | 87.8% |
2633 | D3 receptor | Human | eticlopride | 327 | 67.8% |
2814 | GABAB receptor | Human | GABA | 221 | 52.4% |
2816 | GABAB receptor | Human | baclofen | 285 | 67.6% |
2817 | GABAB receptor | Human | CGP 35348 | 286 | 67.9% |
2820 | GABAB receptor | Human | CGP 46381 | 286 | 67.9% |
2821 | GABAB receptor | Human | CGP 54626A | 286 | 67.9% |
2826 | GABAB receptor | Human | SCH 50911 | 285 | 67.6% |
2828 | GABAB receptor | Human | phaclofen | 285 | 67.6% |
2980 | H1 receptor | Human | doxepin | 329 | 72.6% |
3817 | δ receptor | Human | naltrindole | 181 | 43.5% |
3818 | δ receptor | Mouse | naltrindole | 335 | 72.5% |
3941 | μ receptor | Mouse | β-FNA | 334 | 71.8% |
3979 | NOP receptor | Human | SB 612111 | 203 | 47.6% |
4014 | P2Y1 receptor | Human | MRS2500 | 318 | 75.3% |
4077 | P2Y12 receptor | Human | 2MeSADP | 294 | 62.9% |
4083 | P2Y12 receptor | Human | [3H]2MeSADP | 294 | 62.9% |
5496 | HCN1 | Mouse | cyclic AMP | 72 | 33.8% |
5504 | HCN2 | Mouse | cyclic AMP | 70 | 34.7% |
5505 | HCN2 | Mouse | cyclic GMP | 65 | 32.0% |
6258 | Thyroid hormone receptor-α | Human | triiodothyronine | 180 | 68.1% |
6259 | Thyroid hormone receptor-α | Human | T4 | 175 | 66.2% |
6261 | Thyroid hormone receptor-α | Human | tiratricol | 180 | 68.1% |
6262 | Thyroid hormone receptor-α | Human | sobetirome | 176 | 66.0% |
6263 | Thyroid hormone receptor-α | Human | KB-141 | 184 | 69.6% |
6265 | Thyroid hormone receptor-β | Human | tiratricol | 184 | 68.8% |
6266 | Thyroid hormone receptor-β | Human | sobetirome | 174 | 67.1% |
6267 | Thyroid hormone receptor-β | Human | KB-141 | 181 | 71.4% |
6268 | Thyroid hormone receptor-β | Human | T4 | 188 | 66.5% |
6269 | Thyroid hormone receptor-β | Human | triiodothyronine | 184 | 72.6% |
6273 | Retinoic acid receptor-α | Human | BMS614 | 208 | 88.1% |
6285 | Retinoic acid receptor-β | Human | TTNPB | 212 | 79.0% |
6287 | Retinoic acid receptor-β | Human | tretinoin | 200 | 74.5% |
6288 | Retinoic acid receptor-γ | Human | tretinoin | 200 | 74.5% |
6292 | Retinoic acid receptor-γ | Human | BMS270394 | 104 | 41.9% |
6299 | Peroxisome proliferator-activated receptor-α | Human | GW409544 | 218 | 75.3% |
6309 | Peroxisome proliferator-activated receptor-α | Human | pirinixic acid | 189 | 68.6% |
6325 | Peroxisome proliferator-activated receptor-β/δ | Human | GW2433 | 193 | 70.8% |
6326 | Peroxisome proliferator-activated receptor-β/δ | Human | GW0742X | 192 | 69.5% |
6332 | Peroxisome proliferator-activated receptor-β/δ | Human | L-165041 | 210 | 78.3% |
6338 | Peroxisome proliferator-activated receptor-γ | Human | GW0072 | 106 | 38.9% |
6339 | Peroxisome proliferator-activated receptor-γ | Human | ragaglitazar | 193 | 69.6% |
6344 | Peroxisome proliferator-activated receptor-γ | Human | nTzDpa | 84 | 30.3% |
6357 | Peroxisome proliferator-activated receptor-γ | Human | rosiglitazone | 193 | 45.8% |
6359 | Peroxisome proliferator-activated receptor-γ | Human | netoglitazone | 192 | 69.7% |
6362 | Peroxisome proliferator-activated receptor-γ | Human | farglitazar | 192 | 67.3% |
6364 | Peroxisome proliferator-activated receptor-γ | Human | indomethacin | 193 | 66.9% |
6369 | Peroxisome proliferator-activated receptor-γ | Human | GW409544 | 194 | 68.2% |
6398 | RAR-related orphan receptor-α | Human | cholesterol | 75 | 27.4% |
6399 | RAR-related orphan receptor-α | Human | cholesterol sulphate | 93 | 34.1% |
6410 | Farnesoid X receptor | Human | chenodeoxycholic acid | 183 | 78.1% |
6414 | Farnesoid X receptor | Human | GW4064 | 190 | 80.4% |
6415 | Farnesoid X receptor | Human | fexaramine | 187 | 80.2% |
6426 | Liver X receptor-α | Human | L-783483 | 187 | 65.7% |
6428 | Liver X receptor-α | Human | GW3965 | 187 | 65.7% |
6429 | Liver X receptor-α | Human | T0901317 | 179 | 73.6% |
6433 | Liver X receptor-β | Human | 24(S), 25-epoxycholesterol | 219 | 87.2% |
6435 | Liver X receptor-β | Human | GW3965 | 190 | 74.7% |
6436 | Liver X receptor-β | Human | T0901317 | 182 | 70.4% |
6440 | Constitutive androstane receptor | Human | CITCO | 166 | 67.1% |
6443 | Constitutive androstane receptor | Mouse | androstenol | 83 | 32.0% |
6446 | Vitamin D receptor | Human | calcipotriol | 204 | 77.2% |
6447 | Vitamin D receptor | Human | lexacalcitol | 211 | 81.1% |
6448 | Vitamin D receptor | Human | seocalcitol | 229 | 86.7% |
6450 | Vitamin D receptor | Human | 1,25-dihydroxyvitamin D3 | 204 | 78.4% |
6465 | Pregnane X receptor | Human | SR12813 | 215 | 67.7% |
6467 | Pregnane X receptor | Human | hyperforin | 212 | 66.8% |
6485 | Retinoid X receptor-α | Human | alitretinoin | 165 | 68.9% |
6486 | Retinoid X receptor-α | Human | bexarotene | 169 | 73.7% |
6507 | Estrogen receptor-α | Human | diethylstilbestrol | 186 | 70.9% |
6508 | Estrogen receptor-α | Human | 4-hydroxytamoxifen | 193 | 76.5% |
6509 | Estrogen receptor-α | Human | 17β-estradiol | 173 | 66.7% |
6510 | Estrogen receptor-α | Human | estrone | 184 | 73.2% |
6512 | Estrogen receptor-α | Human | raloxifene | 189 | 73.2% |
6513 | Estrogen receptor-α | Human | estriol | 182 | 69.9% |
6517 | Estrogen receptor-α | Human | 4-hydroxytamoxifen | 193 | 76.5% |
6522 | Estrogen receptor-β | Human | 17β-estradiol | 182 | 75.7% |
6523 | Estrogen receptor-β | Human | genistein | 182 | 71.3% |
6532 | Estrogen receptor-β | Human | R,R-THC | 179 | 65.7% |
6548 | Estrogen-related receptor-γ | Human | 4-hydroxytamoxifen | 167 | 72.2% |
6559 | Androgen receptor | Rat | dihydrotestosterone | 192 | 73.5% |
6569 | Androgen receptor | Human | cyproterone acetate | 191 | 76.3% |
6570 | Glucocorticoid receptor | Human | dexamethasone | 187 | 72.4% |
6573 | Glucocorticoid receptor | Human | cortisol | 185 | 72.2% |
6578 | Mineralocorticoid receptor | Human | deoxycorticosterone | 188 | 73.0% |
6579 | Mineralocorticoid receptor | Human | progesterone | 177 | 69.0% |
6580 | Mineralocorticoid receptor | Human | aldosterone | 188 | 68.0% |
6583 | Mineralocorticoid receptor | Human | dexamethasone | 191 | 75.7% |
6588 | Progesterone receptor | Human | progesterone | 192 | 74.6% |
6593 | Progesterone receptor | Human | levonorgestrel | 177 | 68.2% |
6596 | Progesterone receptor | Human | asoprisnil | 195 | 74.6% |
6597 | RAR-related orphan receptor-γ | Human | 25-hydroxycholesterol | 194 | 77.8% |
6603 | OX1 receptor | Human | suvorexant | 402 | 72.5% |
6604 | OX2 receptor | Human | suvorexant | 371 | 66.2% |
6612 | CXCR4 | Human | isothiourea-1t | 412 | 82.4% |
6614 | CXCR4 | Human | isothiourea-1t | 412 | 82.4% |
6997 | squalene synthase | Human | zaragozic acid A | 247 | 71.7% |
6998 | squalene synthase | Human | zaragozic acid A | 250 | 72.6% |
7089 | farnesyl diphosphate synthase | Human | isopentenyl diphosphate | 296 | 78.7% |
7090 | farnesyl diphosphate synthase | Human | zoledronic acid | 155 | 43.4% |
7091 | farnesyl diphosphate synthase | Human | zoledronic acid | 155 | 43.4% |
7092 | farnesyl diphosphate synthase | Human | risedronate | 158 | 42.0% |
7093 | farnesyl diphosphate synthase | Human | risedronate | 158 | 42.0% |
7116 | farnesyl diphosphate synthase | Human | diphosphoric acid | 184 | 48.8% |
7117 | farnesyl diphosphate synthase | Human | diphosphoric acid | 184 | 48.8% |
7122 | farnesyl diphosphate synthase | Human | alendronate | 155 | 44.0% |
7125 | farnesyl diphosphate synthase | Human | minodronic acid | 159 | 41.8% |
7126 | farnesyl diphosphate synthase | Human | zoledronic acid | 155 | 43.4% |
7127 | farnesyl diphosphate synthase | Human | zoledronic acid | 155 | 43.4% |
7130 | farnesyl diphosphate synthase | Human | risedronate | 158 | 42.0% |
7131 | farnesyl diphosphate synthase | Human | risedronate | 158 | 42.0% |
7136 | farnesyl diphosphate synthase | Human | risedronate | 158 | 42.0% |
7185 | geranylgeranyl diphosphate synthase | Human | geranylgeranyl diphosphate | 182 | 60.1% |
7547 | Retinoic acid receptor-α | Human | Ro 40-6055 | 171 | 63.9% |
7986 | Peroxisome proliferator-activated receptor-α | Human | GW6471 | 98 | 36.1% |
8003 | Peroxisome proliferator-activated receptor-γ | Human | GW9662 | 168 | 35.8% |
8005 | Peroxisome proliferator-activated receptor-γ | Human | diclofenac | 55 | 19.4% |
8010 | Glucocorticoid receptor | Human | [3H]dexamethasone | 187 | 72.4% |
8029 | Androgen receptor | Human | [3H]methyltrienolone | 174 | 65.8% |
9220 | H1 receptor | Human | [11C]doxepin | 329 | 72.6% |
9251 | nicotinic acetylcholine receptor α9 subunit | Human | [3H]methyllycaconitine | 107 | 48.6% |
9403 | PAR1 | Human | vorapaxar | 330 | 68.0% |
9421 | LGR4 | Human | R-spondin-1 | 187 | 36.9% |
9464 | Rev-Erb-β | Human | heme | 187 | 97.4% |
11406 | GluK1 | Rat | dysiherbaine | 204 | 79.0% |
11470 | GluK3 | Rat | kainate | 129 | 49.6% |
13002 | SERT | Human | paroxetine | 407 | 74.0% |
13735 | Leukotriene A4 hydrolase | Human | bestatin | 250 | 40.8% |
13762 | phosphodiesterase 4A | Human | Ro20-1724 | 214 | 60.3% |
13765 | phosphodiesterase 4B | Human | rolipram | 213 | 53.5% |
13768 | phosphodiesterase 4D | Human | Ro20-1724 | 214 | 61.0% |
13769 | phosphodiesterase 4D | Human | rolipram | 214 | 64.2% |
13777 | phosphodiesterase 5A | Human | sildenafil | 247 | 75.9% |
13827 | Ecto-5'-Nucleotidase | Human | αβ-methyleneADP | 469 | 88.0% |
14314 | Androgen receptor | Human | methyltrienolone | 174 | 65.8% |
14315 | Androgen receptor | Human | hydroxyflutamide | 192 | 76.4% |
14316 | Androgen receptor | Human | dihydrotestosterone | 174 | 68.9% |
76926 | P2Y1 receptor | Human | BMS compound 16 [PMID:23368907] | 66 | 15.4% |
77163 | Interleukin-1 receptor, type I | Human | IL-1 receptor antagonist | 295 | 92.2% |
78362 | FFA1 receptor | Human | fasiglifam | 341 | 69.2% |
78396 | Neuronal NOS | Rat | Nωpropyl-L-arginine | 120 | 28.4% |
78401 | farnesyl diphosphate synthase | Human | risedronate | 158 | 42.0% |
78402 | farnesyl diphosphate synthase | Human | alendronate | 155 | 44.0% |
78414 | phosphodiesterase 4D | Human | RS-25344 | 214 | 55.9% |
78427 | plasminogen | Human | tranexamic acid | 60 | 67.0% |
78429 | plasminogen | Human | 6-aminocaproic acid | 31 | 38.0% |
78434 | plasminogen activator, urokinase | Human | compound 4 [PMID: 18163548] | 219 | 83.2% |
78440 | chymase 1 | Human | JNJ-10311795 | 180 | 79.2% |
78451 | MMP13 | Human | compound 1 [PMID: 17935984] | 62 | 36.3% |
78461 | Angiotensin-converting enzyme | Human | lisinopril | 362 | 61.3% |
78463 | Angiotensin-converting enzyme | Human | captopril | 243 | 41.1% |
78465 | dipeptidyl peptidase 4 | Human | sitagliptin | 616 | 84.5% |
78474 | Angiotensin-converting enzyme | Human | enalaprilat | 243 | 41.1% |
78477 | beta-secretase 1 | Human | LY2886721 | 326 | 73.5% |
78481 | dipeptidyl peptidase 4 | Human | vildagliptin | 586 | 79.1% |
78493 | dipeptidyl peptidase 4 | Human | alogliptin | 587 | 79.2% |
78498 | coagulation factor II, thrombin | Human | melagatran | 196 | 75.3% |
78503 | dipeptidyl peptidase 4 | Human | linagliptin | 536 | 72.9% |
78505 | coagulation factor X | Human | apixaban | 134 | 56.8% |
78507 | dipeptidyl peptidase 4 | Human | saxagliptin | 586 | 80.4% |
78508 | renin | Human | aliskiren | 213 | 62.4% |
78509 | coagulation factor X | Human | rivaroxaban | 137 | 58.1% |
78555 | acetylcholinesterase (Cartwright blood group) | Human | donepezil | 376 | 69.2% |
78563 | sphingosine kinase 1 | Human | PF-543 | 147 | 39.4% |
78567 | Phenylethanolamine N-methyltransferase | Human | LY134046 | 235 | 83.0% |
78568 | Monoamine oxidase A | Human | clorgiline | 192 | 36.2% |
78578 | mitogen-activated protein kinase 8 | Human | SP600125 | 116 | 31.2% |
78580 | mitogen-activated protein kinase 10 | Human | SP600125 | 137 | 37.4% |
78583 | mitogen-activated protein kinase 14 | Human | SB203580 | 118 | 32.5% |
78584 | Rho associated coiled-coil containing protein kinase 1 | Human | Y27632 | 287 | 68.9% |
78591 | phosphatidylinositol 4-kinase beta | Human | PIK-93 | 201 | 35.3% |
78600 | H-PGDS | Human | HQL-79 | 152 | 76.3% |
78669 | Leukotriene A4 hydrolase | Human | DG-051 | 250 | 40.8% |
78671 | butyrylcholinesterase | Human | tacrine | 357 | 67.3% |
78675 | acetylcholinesterase (Cartwright blood group) | Human | galantamine | 362 | 66.6% |
78680 | PLA2-G7 | Human | darapladib | 265 | 68.0% |
78741 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Human | imatinib | 135 | 49.1% |
78743 | epidermal growth factor receptor | Human | gefitinib | 138 | 41.6% |
78746 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Human | dasatinib | 133 | 47.7% |
78747 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Human | nilotinib | 135 | 48.4% |
78753 | MET proto-oncogene, receptor tyrosine kinase | Human | crizotinib | 147 | 47.7% |
78759 | kinase insert domain receptor | Human | axitinib | 150 | 47.2% |
78765 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Human | bosutinib | 135 | 46.7% |
78769 | lanosterol synthase | Human | Ro 48-8071 | 607 | 82.8% |
78800 | Peroxisome proliferator-activated receptor-γ | Human | MRL20 | 186 | 67.8% |
78807 | CYP17A1 | Human | abiraterone | 370 | 74.7% |
78858 | carbonic anhydrase 1 | Human | acetazolamide | 119 | 45.4% |
78861 | carbonic anhydrase 1 | Human | methazolamide | 119 | 45.4% |
78867 | carbonic anhydrase 14 | Human | acetazolamide | 121 | 43.0% |
78875 | dihydroorotate dehydrogenase (quinone) | Human | teriflunomide | 322 | 87.5% |
78882 | FK506 binding protein 1A | Human | tacrolimus | 74 | 68.2% |
78885 | histone deacetylase 2 | Human | vorinostat | 275 | 74.3% |
78890 | histone deacetylase 8 | Human | vorinostat | 207 | 54.6% |
78932 | interleukin 1 beta | Human | canakinumab | 111 | 69.6% |
78934 | glutathione-disulfide reductase | Human | oxiglutatione | 447 | 96.7% |
78981 | Mineralocorticoid receptor | Human | spironolactone | 191 | 74.2% |
78983 | Progesterone receptor | Human | progesterone | 195 | 75.8% |
78985 | beta-secretase 1 | Human | LY2811376 | 220 | 49.5% |
78987 | beta-secretase 1 | Human | AZ-4217 | 313 | 75.9% |
78993 | beta-secretase 1 | Human | oxazine 89 | 324 | 79.0% |
79000 | beta-secretase 1 | Human | compound 2 [PMID: 22911925] | 319 | 77.4% |
79003 | Retinoic acid receptor-α | Human | tretinoin | 171 | 63.2% |
79006 | Retinoic acid receptor-β | Human | tretinoin | 200 | 74.5% |
79008 | Retinoic acid receptor-γ | Human | tretinoin | 200 | 74.5% |
79022 | anaplastic lymphoma receptor tyrosine kinase | Human | crizotinib | 123 | 37.3% |
79023 | MET proto-oncogene, receptor tyrosine kinase | Human | crizotinib | 147 | 47.7% |
79043 | B-Raf proto-oncogene, serine/threonine kinase | Human | dabrafenib | 131 | 46.1% |
79050 | MET proto-oncogene, receptor tyrosine kinase | Human | foretinib | 163 | 53.6% |
79159 | histone deacetylase 6 | Human | trichostatin A | 282 | 37.7% |
79163 | histone deacetylase 8 | Human | trichostatin A | 274 | 70.4% |
79182 | peptidylprolyl isomerase A | Human | cyclosporin A | 31 | 18.3% |
79183 | carbonic anhydrase 12 | Human | acetazolamide | 120 | 45.2% |
79189 | carbonic anhydrase 1 | Human | topiramate | 137 | 52.3% |
79197 | carbonic anhydrase 7 | Human | acetazolamide | 118 | 43.5% |
79201 | carbonic anhydrase 7 | Human | ethoxzolamide | 116 | 40.9% |
79214 | phosphodiesterase 4B | Human | roflumilast | 212 | 53.3% |
79264 | Estrogen receptor-α | Human | bazedoxifene | 190 | 77.8% |
79330 | euchromatic histone lysine methyltransferase 1 | Human | BIX-01294 | 85 | 32.2% |
79332 | euchromatic histone lysine methyltransferase 2 | Human | UNC0638 | 95 | 33.2% |
79333 | euchromatic histone lysine methyltransferase 2 | Human | UNC0638 | 92 | 32.2% |
79339 | DOT1 like histone lysine methyltransferase | Human | bromo-deaza-SAH | 113 | 26.6% |
79340 | DOT1 like histone lysine methyltransferase | Human | pinometostat | 81 | 18.8% |
79341 | DOT1 like histone lysine methyltransferase | Human | EPZ004777 | 166 | 46.9% |
79342 | DOT1 like histone lysine methyltransferase | Human | SGC0946 | 255 | 61.5% |
79343 | SET and MYND domain containing 2 | Human | AZ505 | 154 | 35.3% |
79346 | PHD finger protein 8 | Human | daminozide | 131 | 34.8% |
79359 | protein arginine methyltransferase 3 | Human | compound 1 [PMID: 22795084] | 223 | 65.3% |
79363 | cyclin dependent kinase 2 | Human | dinaciclib | 125 | 41.6% |
79368 | cyclin dependent kinase 6 | Human | palbociclib | 145 | 46.8% |
79385 | SERT | Human | escitalopram | 453 | 82.3% |
79391 | CYP19A1 | Human | exemestane | 363 | 72.0% |
79412 | COX-2 | Human | meclofenamic acid | 184 | 33.2% |
79436 | farnesyl diphosphate synthase | Human | pamidronic acid | 158 | 41.9% |
79448 | phosphodiesterase 5A | Human | tadalafil | 53 | 14.3% |
79463 | phosphodiesterase 5A | Human | vardenafil | 247 | 75.9% |
79481 | Peroxisome proliferator-activated receptor-γ | Human | rosiglitazone | 192 | 70.5% |
79499 | COX-2 | Human | mefenamic acid | 182 | 32.8% |
79503 | anaplastic lymphoma receptor tyrosine kinase | Human | ceritinib | 135 | 36.5% |
79510 | farnesyl diphosphate synthase | Human | ibandronic acid | 159 | 45.1% |
79522 | dihydrofolate reductase | Human | methotrexate | 130 | 69.4% |
79525 | maltase-glucoamylase | Human | miglitol | 606 | 69.1% |
79526 | epidermal growth factor receptor | Human | erlotinib | 138 | 41.1% |
79537 | L-Phenylalanine hydroxylase | Human | sapropterin | 86 | 26.2% |
79548 | epidermal growth factor receptor | Human | afatinib | 207 | 62.4% |
79553 | B-Raf proto-oncogene, serine/threonine kinase | Human | vemurafenib | 134 | 47.3% |
79619 | thymidylate synthetase | Mouse | raltitrexed | 233 | 75.6% |
79620 | thymidylate synthetase | Human | raltitrexed | 179 | 61.4% |
79677 | kinase insert domain receptor | Human | nintedanib | 151 | 48.2% |
79680 | kinase insert domain receptor | Human | tivozanib | 158 | 44.5% |
79688 | spleen associated tyrosine kinase | Human | tamatinib | 125 | 42.6% |
79689 | kinase insert domain receptor | Human | lenvatinib | 157 | 50.5% |
79711 | aldo-keto reductase family 1 member B | Human | tolrestat | 284 | 89.6% |
79767 | Progesterone receptor | Human | ulipristal acetate | 177 | 68.2% |
79768 | Progesterone receptor | Human | ulipristal acetate | 177 | 68.2% |
79786 | anaplastic lymphoma receptor tyrosine kinase | Human | loratinib | 149 | 45.3% |
79896 | CREB binding protein | Human | ischemin | 64 | 52.1% |
79898 | bromodomain containing 4 | Human | MS436 | 88 | 68.5% |
79900 | bromodomain containing 4 | Human | (+)-JQ1 | 97 | 75.6% |
79901 | bromodomain containing 4 | Human | MS417 | 97 | 75.6% |
79904 | bromodomain containing 4 | Human | I-BET-762 | 97 | 75.6% |
79905 | bromodomain containing 2 | Human | I-BET-762 | 68 | 58.8% |
79907 | bromodomain containing 2 | Human | GW841819X | 66 | 42.5% |
79909 | bromodomain containing 4 | Human | GW841819X | 69 | 53.5% |
79910 | bromodomain containing 4 | Human | BzT-7 | 69 | 53.5% |
79912 | bromodomain containing 4 | Human | compound 4d [PMID: 21851057] | 69 | 53.5% |
79914 | bromodomain containing 2 | Human | I-BET151 | 66 | 42.2% |
79916 | bromodomain containing 4 | Human | I-BET151 | 69 | 53.5% |
79917 | poly(ADP-ribose) polymerase 1 | Human | olaparib | 127 | 46.5% |
79918 | poly(ADP-ribose) polymerase 2 | Human | olaparib | 139 | 37.5% |
79925 | bromodomain containing 4 | Human | PFI-1 | 69 | 53.5% |
79926 | bromodomain containing 4 | Human | BI-2536 | 60 | 46.5% |
79928 | polo like kinase 1 | Human | BI-2536 | 127 | 42.9% |
79935 | bromodomain containing 4 | Human | XD14 | 84 | 65.4% |
79936 | bromodomain containing 4 | Human | XD1 | 65 | 50.8% |
79939 | bromodomain containing 4 | Human | isoxazole azepine compound 3 | 97 | 75.0% |
79940 | bromodomain containing 4 | Human | compound 15 (Hay et al., 2013) | 69 | 53.5% |
79941 | CREB binding protein | Human | SGC-CBP30 | 69 | 57.1% |
79942 | E1A binding protein p300 | Human | SGC-CBP30 | 72 | 61.2% |
79959 | Estrogen receptor-α | Human | lasofoxifene | 180 | 70.8% |
80081 | Progesterone receptor | Human | tanaproget | 177 | 68.0% |
80082 | aldo-keto reductase family 1 member B | Human | sorbinil | 279 | 88.0% |
80083 | aldo-keto reductase family 1 member B | Human | lidorestat | 290 | 90.6% |
80084 | aldo-keto reductase family 1 member B | Human | zopolrestat | 291 | 91.8% |
80085 | aldo-keto reductase family 1 member B | Human | zenarestat | 290 | 91.5% |
80088 | epidermal growth factor receptor | Human | AEE788 | 138 | 41.8% |
80146 | mitogen-activated protein kinase 14 | Human | AZD6703 | 139 | 37.9% |
80157 | mitogen-activated protein kinase kinase 1 | Human | selumetinib | 138 | 40.2% |
80200 | AKT serine/threonine kinase 1 | Human | AZD5363 | 281 | 82.6% |
80208 | checkpoint kinase 1 | Human | AZD7762 | 167 | 60.6% |
80251 | SRC proto-oncogene, non-receptor tyrosine kinase | Human | saracatinib | 132 | 24.5% |
80263 | poly(ADP-ribose) polymerase 1 | Human | rucaparib | 145 | 40.9% |
80268 | β2-adrenoceptor | Human | carazolol | 332 | 66.2% |
80282 | anaplastic lymphoma receptor tyrosine kinase | Human | brigatinib | 149 | 46.4% |
80285 | anaplastic lymphoma receptor tyrosine kinase | Human | brigatinib | 149 | 46.4% |
80292 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | CH5132799 | 161 | 16.6% |
80328 | Pim-1 proto-oncogene, serine/threonine kinase | Human | Akt inhibitor X | 138 | 47.6% |
80334 | cyclin dependent kinase 5 | Human | aloisine A | 103 | 34.9% |
80337 | glycogen synthase kinase 3 beta | Human | alsterpaullone | 116 | 27.1% |
80348 | aurora kinase A | Human | aurora kinase inhibitor III | 230 | 84.2% |
80356 | Pim-1 proto-oncogene, serine/threonine kinase | Human | ruboxistaurin | 143 | 45.5% |
80420 | glycogen synthase kinase 3 beta | Human | GSK-3beta inhibitor VIII | 127 | 30.4% |
80427 | protein kinase, cAMP-dependent, catalytic, alpha subunit | Human | H-89 | 278 | 79.6% |
80430 | glycogen synthase kinase 3 beta | Human | indirubin-3'-monoxime | 127 | 29.7% |
80436 | Janus kinase 2 | Human | JAK inhibitor I | 140 | 47.8% |
80437 | Janus kinase 3 | Human | JAK inhibitor I | 129 | 39.1% |
80438 | tyrosine kinase 2 | Human | JAK inhibitor I | 128 | 42.1% |
80504 | coagulation factor X | Human | eribaxaban | 136 | 57.7% |
80519 | epidermal growth factor receptor | Human | PD 174265 | 115 | 34.1% |
80524 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | PI 3-Kg inhibitor | 155 | 15.9% |
80528 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | PI 3-Kg inhibitor II | 155 | 15.9% |
80549 | FK506 binding protein 1A | Human | sirolimus | 95 | 87.9% |
80557 | cyclin dependent kinase 2 | Human | seliciclib | 125 | 41.6% |
80561 | mitogen-activated protein kinase 14 | Human | SB220025 | 118 | 30.9% |
80574 | cyclin dependent kinase 2 | Human | SU9516 | 115 | 38.3% |
80583 | transforming growth factor beta receptor 1 | Human | TGF-beta RI kinase inhibitor | 141 | 42.9% |
80594 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Human | wortmannin | 701 | 64.2% |
80614 | mitogen-activated protein kinase 1 | Human | ERK inhibitor II | 116 | 31.3% |
80623 | bromodomain containing 2 | Human | ME bromodomain inhibitor | 66 | 57.0% |
80624 | bromodomain containing 2 | Human | ET bromodomain inhibitor | 66 | 57.0% |
80625 | bromodomain containing 4 | Human | compound 1 [PMID: 25408830] | 60 | 38.6% |
80630 | bromodomain and PHD finger containing 1 | Human | compound 3 [PMID: 25408830] | 76 | 63.6% |
80639 | mitogen-activated protein kinase 14 | Human | talmapimod | 133 | 36.5% |
80641 | mitogen-activated protein kinase 14 | Human | PH-797804 | 82 | 22.5% |
80658 | MMP12 | Human | RXP470.1 | 95 | 59.1% |
80672 | mitogen-activated protein kinase 14 | Human | BMS-582949 | 134 | 36.3% |
80692 | Androgen receptor | Human | andarine | 196 | 78.3% |
80705 | Neutral endopeptidase | Human | sacubitrilat | 617 | 88.3% |
80713 | Angiotensin-converting enzyme 2 | Human | MLN-4760 | 243 | 39.3% |
80716 | cyclin dependent kinase 2 | Human | roniciclib | 135 | 45.0% |
80719 | fibroblast growth factor receptor 1 | Human | BGJ-398 | 150 | 39.0% |
80724 | Angiotensin-converting enzyme | Human | RXP-407 | 243 | 38.5% |
80753 | AKT serine/threonine kinase 1 | Human | ipatasertib | 282 | 82.6% |
80759 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | apitolisib | 163 | 16.8% |
80764 | spleen associated tyrosine kinase | Human | entospletinib | 136 | 46.4% |
80775 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Human | bafetinib | 135 | 45.7% |
80784 | 3-phosphoinositide dependent protein kinase 1 | Human | 7-hydroxystaurosporine | 135 | 43.4% |
80797 | Janus kinase 2 | Human | filgotinib | 140 | 47.8% |
80802 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 | Human | PFI-3 | 63 | 51.2% |
80808 | polo like kinase 1 | Human | NMS-P937 | 138 | 44.1% |
80833 | mitogen-activated protein kinase kinase 1 | Human | PD 0325901 | 141 | 41.1% |
80835 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Human | PF-04691502 | 164 | 17.2% |
80836 | aurora kinase A | Human | danusertib | 116 | 41.1% |
80839 | cyclin dependent kinase 2 | Human | milciclib | 128 | 41.1% |
80845 | mitogen-activated protein kinase kinase 1 | Human | refametinib | 137 | 39.9% |
80860 | protein kinase C alpha | Human | sotrastaurin | 137 | 38.0% |
80866 | polo like kinase 1 | Human | volasertib | 127 | 37.6% |
80880 | Insulin-like growth factor I receptor | Human | BMS-754807 | 154 | 48.6% |
80886 | Janus kinase 2 | Human | BMS-911543 | 140 | 46.5% |
80974 | mechanistic target of rapamycin | Human | PI-103 | 173 | 14.7% |
80998 | HCK proto-oncogene, Src family tyrosine kinase | Human | PP121 | 132 | 28.9% |
81001 | glycogen synthase kinase 3 beta | Human | CHIR-99021 | 127 | 29.8% |
81018 | farnesyltransferase, CAAX box, beta | Human | tipifarnib | 267 | 60.9% |
81034 | ribosomal protein S6 kinase B1 | Human | PF-4708671 | 281 | 81.2% |
81041 | ribosomal protein S6 kinase A3 | Human | BI-D1870 | 263 | 79.4% |
81051 | mitogen-activated protein kinase 14 | Human | VX-745 | 138 | 37.8% |
81064 | MET proto-oncogene, receptor tyrosine kinase | Human | SGX-523 | 147 | 46.1% |
81065 | B-Raf proto-oncogene, serine/threonine kinase | Human | GDC-0879 | 121 | 36.5% |
81068 | mitogen-activated protein kinase-activated protein kinase 2 | Human | PF-3644022 | 138 | 41.9% |
81069 | mitogen-activated protein kinase-activated protein kinase 2 | Human | PF-3644022 | 138 | 41.9% |
81080 | casein kinase 1 delta | Human | PF-4800567 | 133 | 44.6% |
81086 | CDC like kinase 1 | Human | KH-CB19 | 158 | 46.6% |
81087 | CDC like kinase 3 | Human | KH-CB19 | 159 | 41.5% |
81089 | mitogen-activated protein kinase 1 | Human | SCH772984 | 137 | 37.7% |
81090 | mitogen-activated protein kinase 1 | Human | SCH772984 | 137 | 37.7% |
81091 | mitogen-activated protein kinase 7 | Human | XMD8-92 | 129 | 37.0% |
81100 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | pictilisib | 163 | 16.9% |
81104 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | AZD6482 | 163 | 16.8% |
81109 | aurora kinase A | Human | MK-5108 | 118 | 43.5% |
81113 | TANK binding kinase 1 | Human | MRT67307 | 141 | 21.2% |
81115 | polo like kinase 1 | Human | BI-2536 | 127 | 42.9% |
81116 | polo like kinase 2 | Human | BI-2536 | 236 | 76.3% |
81122 | Bruton tyrosine kinase | Human | CGI1746 | 139 | 50.9% |
81137 | mitogen-activated protein kinase kinase kinase 7 | Human | NG-25 | 100 | 31.5% |
81146 | mitogen-activated protein kinase kinase kinase 7 | Human | 5Z-7-oxozeaenol | 134 | 42.2% |
81169 | kinase insert domain receptor | Human | axitinib | 150 | 47.2% |
81173 | B-Raf proto-oncogene, serine/threonine kinase | Human | CHIR-265 | 133 | 47.0% |
81175 | kinase insert domain receptor | Human | sorafenib | 158 | 50.8% |
81179 | epidermal growth factor receptor | Human | erlotinib | 138 | 41.1% |
81180 | epidermal growth factor receptor | Human | gefitinib | 138 | 41.6% |
81202 | MET proto-oncogene, receptor tyrosine kinase | Human | foretinib | 163 | 53.6% |
81205 | MET proto-oncogene, receptor tyrosine kinase | Human | SGX-523 | 147 | 46.1% |
81210 | aurora kinase A | Human | MLN-8054 | 137 | 50.0% |
81211 | aurora kinase A | Human | MLN-8054 | 137 | 50.0% |
81212 | aurora kinase A | Human | tozasertib | 136 | 50.6% |
81213 | aurora kinase B | Human | tozasertib | 125 | 42.5% |
81214 | aurora kinase A | Human | tozasertib | 136 | 50.6% |
81218 | B-Raf proto-oncogene, serine/threonine kinase | Human | PLX-4720 | 133 | 47.1% |
81219 | B-Raf proto-oncogene, serine/threonine kinase | Human | PLX-4720 | 133 | 47.1% |
81225 | KIT proto-oncogene receptor tyrosine kinase | Human | sunitinib | 159 | 47.0% |
81286 | KIT proto-oncogene receptor tyrosine kinase | Human | sunitinib | 159 | 47.0% |
81287 | kinase insert domain receptor | Human | sunitinib | 158 | 44.5% |
81294 | spleen associated tyrosine kinase | Human | tamatinib | 125 | 42.6% |
81305 | kinase insert domain receptor | Human | sorafenib | 158 | 50.8% |
81311 | B-Raf proto-oncogene, serine/threonine kinase | Human | sorafenib | 133 | 47.8% |
81345 | Rho associated coiled-coil containing protein kinase 1 | Human | fasudil | 287 | 68.9% |
81347 | Rho associated coiled-coil containing protein kinase 1 | Human | fasudil | 287 | 68.9% |
81366 | cell division cycle 7 | Human | XL413 | 127 | 34.9% |
81398 | SRC proto-oncogene, non-receptor tyrosine kinase | Human | bosutinib | 132 | 45.8% |
81423 | casein kinase 2, alpha 1 polypeptide subunit | Human | CX-4945 | 131 | 38.6% |
81435 | casein kinase 2, alpha 1 polypeptide subunit | Human | compound 1a [PMID: 24900749] | 125 | 37.2% |
81443 | serine/threonine kinase 10 | Human | bosutinib | 269 | 90.8% |
81444 | mitogen-activated protein kinase kinase kinase 5 | Human | compound 10 [PMID: 23147077] | 128 | 47.2% |
81449 | AKT serine/threonine kinase 2 | Human | GSK690693 | 260 | 77.8% |
81491 | EPH receptor A3 | Human | compound 66 [PMID: 19788238] | 130 | 35.7% |
81500 | beta adrenergic receptor kinase 1 | Human | balanol | 141 | 20.3% |
81546 | mitogen-activated protein kinase kinase 6 | Human | staurosporine | 128 | 43.8% |
81547 | death associated protein kinase 1 | Human | staurosporine | 143 | 51.1% |
81554 | Rho associated coiled-coil containing protein kinase 1 | Human | RKI-1447 | 284 | 69.0% |
81576 | Pim-1 proto-oncogene, serine/threonine kinase | Human | compound 20 [PMID: 22136433] | 142 | 44.9% |
81577 | Pim-3 proto-oncogene, serine/threonine kinase | Human | compound 20 [PMID: 22136433] | 142 | 44.9% |
81635 | IL2 inducible T-cell kinase | Human | compound 7 [PMID: 22464456] | 131 | 48.9% |
81639 | mitogen-activated protein kinase kinase kinase 14 | Human | compound 31 [PMID: 23374866] | 128 | 35.7% |
81653 | serine/threonine kinase 24 | Human | bosutinib | 122 | 39.2% |
81673 | mitogen-activated protein kinase-activated protein kinase 2 | Human | compound 16 [PMID: 17480064] | 138 | 41.0% |
81707 | Rho associated coiled-coil containing protein kinase 1 | Human | Y27632 | 287 | 68.9% |
81767 | mechanistic target of rapamycin | Human | PP-242 | 174 | 14.7% |
81808 | transforming growth factor beta receptor 1 | Human | SB-431542 | 141 | 45.3% |
81842 | lysine demethylase 6B | Human | IOX1 | 92 | 27.4% |
81844 | WD repeat domain 5 | Human | OICR-9429 | 257 | 82.1% |
81847 | bromodomain adjacent to zinc finger domain 2B | Human | GSK2801 | 63 | 53.0% |
81848 | SET domain containing lysine methyltransferase 7 | Human | (R)-PFI-2 | 96 | 36.0% |
81854 | SET and MYND domain containing 2 | Human | LLY-507 | 119 | 26.8% |
81894 | amyloid P component, serum | Human | CPHPC | 91 | 44.1% |
81910 | purine nucleoside phosphorylase | Human | forodesine | 225 | 77.5% |
81911 | poly(ADP-ribose) polymerase 1 | Human | niraparib | 145 | 40.2% |
81924 | protein arginine methyltransferase 5 | Human | EPZ015666 | 272 | 42.0% |
81928 | Monoamine oxidase B | Human | safinamide | 334 | 64.0% |
81929 | Monoamine oxidase B | Human | safinamide | 334 | 64.0% |
81930 | squalene synthase | Human | compound 15a [PMID: 22464687] | 273 | 80.0% |
81931 | MET proto-oncogene, receptor tyrosine kinase | Human | AM7 | 128 | 41.0% |
81932 | leucine rich repeat kinase 2 | Human | PF-06454589 | 122 | 41.9% |
81938 | dipeptidyl peptidase 4 | Human | compound 1 (Xiao et al. 2014) | 616 | 81.8% |
81939 | bromodomain adjacent to zinc finger domain 2B | Human | compound 1 [PMID: 25719566] | 64 | 53.8% |
81940 | bromodomain containing 4 | Human | compound 7d [PMID: 25703523] | 60 | 46.5% |
81941 | bromodomain adjacent to zinc finger domain 2B | Human | compound 7 [PMID: 25719566] | 58 | 48.7% |
81944 | Janus kinase 2 | Human | decernotinib | 139 | 46.9% |
81950 | CYP11B2 | Human | fadrozole | 373 | 77.0% |
81953 | poly(ADP-ribose) polymerase 1 | Human | talazoparib | 230 | 61.9% |
81954 | poly(ADP-ribose) polymerase 2 | Human | talazoparib | 231 | 62.5% |
81962 | BCL2, apoptosis regulator | Human | navitoclax | 103 | 61.4% |
82033 | glutaminyl-peptide cyclotransferase | Human | PBD150 | 216 | 65.3% |
82041 | bromodomain containing 4 | Human | LY 294002 | 66 | 51.2% |
82072 | transthyretin | Human | tafamidis | 104 | 81.1% |
82102 | bromodomain containing 9 | Human | I-BRD9 | 68 | 63.2% |
82125 | A2A receptor | Human | UK-432,097 | 360 | 73.6% |
82200 | poly (ADP-ribose) polymerase 3 | Human | ME0328 | 228 | 63.6% |
82209 | B-Raf proto-oncogene, serine/threonine kinase | Human | AZ628 | 115 | 40.6% |
82212 | glycogen synthase kinase 3 beta | Human | AZD2858 | 118 | 25.2% |
82339 | protein arginine methyltransferase 3 | Human | SGC707 | 223 | 65.3% |
82362 | bromodomain containing 9 | Human | LP99 | 66 | 52.8% |
82372 | bromodomain and PHD finger containing 1 | Human | PFI-4 | 80 | 68.1% |
82388 | M1 receptor | Human | tiotropium | 328 | 63.5% |
82425 | LPA1 receptor | Human | ONO-3080573 | 332 | 72.1% |
82426 | LPA1 receptor | Human | ONO-9780307 | 355 | 76.3% |
82427 | LPA1 receptor | Human | ONO-9910539 | 355 | 76.3% |
82443 | insulin degrading enzyme | Human | NTE-1 | 408 | 41.2% |
82444 | insulin degrading enzyme | Human | NTE-2 | 409 | 41.3% |
82445 | insulin degrading enzyme | Human | quinoline 2 | 282 | 28.4% |
82448 | furin, paired basic amino acid cleaving enzyme | Human | MI-1148 | 216 | 44.6% |
82454 | fatty acid synthase | Human | GSK2194069 | 469 | 70.9% |
82515 | MMP13 | Human | compound 15 [PMID: 22017539] | 113 | 65.5% |
82516 | aldo-keto reductase family 1 member B | Human | AK198 | 284 | 89.6% |
82517 | CYP17A1 | Human | galeterone | 370 | 74.7% |
82521 | ATPase family, AAA domain containing 2 | Human | compound 60 [PMID: 26155854] | 59 | 44.6% |
82602 | ADAM17 | Human | IK-862 | 102 | 38.7% |
82636 | beta-secretase 1 | Human | compound 16 [PMID: 23412139] | 326 | 82.3% |
82660 | CD38 | Human | isatuximab | 160 | 62.1% |
82672 | poly(ADP-ribose) polymerase 2 | Human | compound 10b [PMID: 26222319] | 146 | 39.9% |
82673 | poly(ADP-ribose) polymerase 1 | Human | compound 10b [PMID: 26222319] | 127 | 34.8% |
82674 | ATPase family, AAA domain containing 2 | Human | compound 33 [PMID: 26230603] | 71 | 53.8% |
82686 | bromodomain containing 4 | Human | RVX 208 | 83 | 71.9% |
82687 | bromodomain containing 2 | Human | RVX 208 | 83 | 71.9% |
82690 | Peroxisome proliferator-activated receptor-γ | Human | resveratrol | 79 | 27.2% |
82694 | lysine demethylase 4A | Human | compound 6a [PMID: 18942826] | 145 | 37.8% |
82695 | lysine demethylase 4E | Human | compound 6a [PMID: 18942826] | 145 | 40.2% |
82697 | CYP2D6 | Human | ajmalicine | 374 | 77.9% |
82710 | CYP2A6 | Human | compound 39a [PMID: 15634016] | 374 | 78.4% |
82796 | retinol binding protein 4 | Human | A1120 | 101 | 47.2% |
82822 | CYP3A4 | Human | ritonavir | 374 | 76.9% |
82826 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | compound 82 [PMID: 21332118] | 155 | 16.0% |
82830 | mechanistic target of rapamycin | Human | compound 82 [PMID: 21332118] | 155 | 16.0% |
82842 | mPGES1 | Human | compound 30 [PMID: 15953724] | 107 | 68.8% |
82872 | RTP Type G | Human | compound 1 [PMID: 21882820] | 89 | 28.4% |
82891 | mechanistic target of rapamycin | Human | torin 2 | 172 | 14.6% |
82905 | MMP1 | Human | CGS-27023A | 61 | 35.7% |
82936 | fibroblast growth factor receptor 4 | Human | BLU9931 | 119 | 39.3% |
82972 | NOP receptor | Human | SB 612111 | 203 | 47.6% |
82981 | fatty acid binding protein 4 | Mouse | HTS01037 | 113 | 85.5% |
83004 | GluK2 | Rat | kainate | 179 | 68.2% |
83037 | DOT1 like histone lysine methyltransferase | Human | bromo-deaza-SAH | 113 | 26.6% |
83076 | Rev-Erb-β | Human | cobalt protoporphyrin IX | 192 | 96.0% |
83084 | Retinoic acid receptor-α | Human | Ro 40-6055 | 171 | 63.9% |
83093 | Peroxisome proliferator-activated receptor-γ | Human | bexarotene | 169 | 73.7% |
83094 | Estrogen-related receptor-γ | Human | GSK5182 | 173 | 76.1% |
83095 | Estrogen-related receptor-γ | Human | 4-hydroxytamoxifen | 167 | 72.2% |
83096 | Estrogen receptor-α | Human | 4-hydroxytamoxifen | 193 | 76.5% |
83118 | mitogen-activated protein kinase kinase 1 | Human | cobimetinib | 148 | 48.8% |
83121 | MET proto-oncogene, receptor tyrosine kinase | Human | tepotinib | 147 | 50.2% |
83128 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | AMG319 | 162 | 16.8% |
83160 | p21 (RAC1) activated kinase 1 | Human | PF-3758309 | 263 | 87.3% |
83169 | p21 (RAC1) activated kinase 6 | Human | PF-3758309 | 129 | 44.0% |
83171 | p21 (RAC1) activated kinase 1 | Human | FRAX597 | 244 | 81.0% |
83183 | neurotrophic receptor tyrosine kinase 2 | Human | GW-2580 | 126 | 41.8% |
83194 | B-Raf proto-oncogene, serine/threonine kinase | Human | LY3009120 | 124 | 40.1% |
83214 | bromodomain containing 9 | Human | BI-9564 | 65 | 52.0% |
83226 | SET and MYND domain containing 2 | Human | BAY-598 | 155 | 35.6% |
83227 | protein arginine methyltransferase 5 | Human | GSK591 | 281 | 43.4% |
83231 | protein arginine methyltransferase 6 | Human | MS023 | 269 | 71.3% |
83232 | protein arginine methyltransferase 6 | Human | MS023 | 269 | 71.3% |
83246 | B-Raf proto-oncogene, serine/threonine kinase | Human | BGB-283 | 132 | 44.9% |
83277 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | omipalisib | 161 | 16.6% |
83291 | lysine demethylase 5B | Human | GSK-J1 | 162 | 33.5% |
83383 | Arginase I | Human | compound 9 [PMID: 23472952] | 177 | 56.1% |
83384 | Arginase II | Human | compound 9 [PMID: 23472952] | 177 | 57.5% |
83385 | indoleamine 2,3-dioxygenase 1 | Human | NLG919 | 136 | 33.5% |
83479 | peptidyl arginine deiminase 4 | Human | o-F-amidine | 299 | 44.4% |
83481 | Neutral endopeptidase | Human | compound 1a [PMID: 25692029] | 612 | 87.8% |
83483 | Leukotriene A4 hydrolase | Human | compound 1a [PMID: 25692029] | 430 | 69.6% |
83518 | bromodomain containing 4 | Human | CPI-0610 | 97 | 75.0% |
83541 | receptor interacting serine/threonine kinase 2 | Human | GSK583 | 141 | 42.9% |
83546 | OX1 receptor | Human | SB-674042 | 401 | 72.3% |
83551 | SERT | Human | escitalopram | 407 | 74.0% |
83552 | SERT | Human | paroxetine | 407 | 74.0% |
83559 | Neuronal NOS | Human | compound 14j [PMID: 27050842] | 115 | 27.1% |
83560 | Neuronal NOS | Rat | compound 14j [PMID: 27050842] | 115 | 27.0% |
83605 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Human | rebastinib | 135 | 48.4% |
83611 | epidermal growth factor receptor | Human | WZ4002 | 124 | 37.2% |
83652 | κ receptor | Human | JDTic | 369 | 76.7% |
83653 | κ receptor | Human | JDTic | 369 | 76.7% |
83677 | transmembrane protein 173 | Human | 2'3'-cGAMP | 103 | 42.1% |
83697 | mitogen-activated protein kinase 1 | Human | GDC-0994 | 137 | 38.6% |
83711 | A2A receptor | Human | compound 4g [PMID: 22220592] | 107 | 32.2% |
83738 | heat shock protein 90 alpha family class A member 1 | Human | BIIB021 | 134 | 56.1% |
83739 | heat shock protein 90 alpha family class A member 1 | Human | SNX0723 | 132 | 56.2% |
83743 | Bruton tyrosine kinase | Human | GDC-0834 | 145 | 53.3% |
83753 | TTK protein kinase | Human | MPS1-IN-1 | 133 | 42.2% |
83879 | mitogen-activated protein kinase 14 | Human | TAK-715 | 142 | 39.0% |
83925 | dual specificity tyrosine phosphorylation regulated kinase 1A | Human | harmine | 122 | 33.0% |
83947 | pyruvate dehydrogenase kinase 1 | Human | AZD7545 | 137 | 33.4% |
83954 | Pim-1 proto-oncogene, serine/threonine kinase | Human | LGB321 | 143 | 43.4% |
83964 | casein kinase 1 delta | Human | PF-670462 | 126 | 42.2% |
83976 | mitogen-activated protein kinase 1 | Human | VTX-11e | 137 | 37.7% |
83982 | mitogen-activated protein kinase 10 | Human | JNK inhibitor 9l | 134 | 36.8% |
83984 | phosphatidylinositol 3-kinase catalytic subunit type 3 | Human | PIK-III | 128 | 20.3% |
83989 | protein tyrosine kinase 2 | Human | PF-562271 | 143 | 51.4% |
84009 | spleen associated tyrosine kinase | Human | GSK143 | 136 | 48.7% |
84035 | TTK protein kinase | Human | MPI-0479605 | 135 | 42.9% |
84036 | TTK protein kinase | Human | AZ3146 | 124 | 39.4% |
84037 | TTK protein kinase | Human | NMS-P715 | 155 | 49.2% |
84039 | polo like kinase 1 | Human | Ro3280 | 126 | 34.9% |
84040 | polo like kinase 1 | Human | Ro3280 | 126 | 34.9% |
84043 | LCK proto-oncogene, Src family tyrosine kinase | Human | PP2 | 132 | 47.1% |
84085 | TTK protein kinase | Human | BAY1161909 | 151 | 48.1% |
84094 | CCR2 | Human | BMS-681 | 419 | 82.4% |
84096 | CCR2 | Human | CCR2-RA-[R] | 410 | 80.7% |
84134 | mitogen-activated protein kinase kinase kinase 7 | Human | compound 12 [PMID: 27448772] | 134 | 42.2% |
84261 | mixed lineage kinase domain like pseudokinase | Human | MLKL compound 1 | 141 | 49.5% |
84262 | mixed lineage kinase domain like pseudokinase | Human | MLKL compound 1 | 141 | 49.5% |
84269 | ATPase family, AAA domain containing 2 | Human | GSK8814 | 65 | 49.2% |
84270 | ATPase family, AAA domain containing 2 | Human | GSK8814 | 65 | 49.2% |
84272 | ATPase family, AAA domain containing 2 | Human | GSK8814 | 65 | 49.2% |
84275 | bromodomain and PHD finger containing 1 | Human | OF-1 | 76 | 64.7% |
84279 | embryonic ectoderm development | Human | A-395 | 336 | 90.1% |
84326 | receptor interacting serine/threonine kinase 1 | Human | GSK2982772 | 132 | 43.2% |
84335 | PAR2 | Human | AZ3451 | 136 | 21.8% |
84336 | PAR2 | Human | AZ3451 | 136 | 21.8% |
84366 | glucagon receptor | Human | NNC0640 | 59 | 10.1% |
84391 | GLP-1 receptor | Human | Peptide 5 [PMID: 28562585] | 354 | 83.6% |
84392 | GLP-1 receptor | Human | Peptide 5 [PMID: 28562585] | 354 | 83.6% |
84430 | CB1 receptor | Human | AM11542 | 120 | 27.2% |
84439 | phosphodiesterase 10A | Human | PF-2545920 | 206 | 53.9% |
84445 | PAR2 | Human | AZ3451 | 136 | 21.8% |
84447 | PAR2 | Human | AZ8838 | 349 | 56.2% |
84448 | PAR2 | Human | AZ8838 | 349 | 56.2% |
84449 | PAR2 | Human | AZ8838 | 349 | 56.2% |
84482 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | Human | pictilisib | 163 | 16.9% |
84487 | Bruton tyrosine kinase | Human | ibrutinib | 133 | 47.3% |
84537 | ETB receptor | Human | K-8794 | 337 | 72.4% |
84539 | Glucocorticoid receptor | Human | GSK866 | 191 | 73.9% |
84541 | beta-secretase 1 | Human | AMG-8718 | 220 | 53.3% |
84542 | mitogen-activated protein kinase kinase kinase 7 | Human | Takinib | 134 | 43.3% |
84577 | interleukin 1 receptor associated kinase 4 | Human | PF-06650833 | 138 | 42.8% |
84619 | Glucocorticoid receptor | Human | budesonide | 190 | 67.5% |
84743 | receptor interacting serine/threonine kinase 1 | Human | necrostatin-1s | 96 | 32.3% |
84753 | glucagon receptor | Human | NNC1702 | 518 | 89.9% |
84813 | Pim-1 proto-oncogene, serine/threonine kinase | Human | PIM447 | 143 | 43.4% |
84824 | chymase 1 | Human | compound 7f [PMID: 29191554] | 179 | 78.8% |
84827 | PLA2-G7 | Human | darapladib | 263 | 67.5% |
84828 | PLA2-G7 | Human | darapladib | 263 | 67.5% |
84829 | PLA2-G7 | Human | (S)-23 [PMID: 27933945] | 269 | 69.1% |
84830 | PLA2-G7 | Human | (S)-23 [PMID: 27933945] | 269 | 69.1% |
84891 | beta-secretase 1 | Human | RO5508887 | 325 | 79.2% |
84900 | heat shock protein 90 alpha family class A member 1 | Human | alvespimycin | 134 | 61.9% |
84911 | mitogen-activated protein kinase 10 | Human | tanzisertib | 137 | 29.3% |
84917 | MET proto-oncogene, receptor tyrosine kinase | Human | merestinib | 140 | 43.8% |
84918 | MET proto-oncogene, receptor tyrosine kinase | Human | merestinib | 140 | 43.8% |
84961 | Bruton tyrosine kinase | Human | BMS-986142 | 119 | 44.2% |
84981 | RAR-related orphan receptor-γ | Human | TAK-828F | 103 | 47.2% |
85059 | spleen associated tyrosine kinase | Human | tamatinib | 125 | 42.6% |
85060 | dipeptidyl peptidase 4 | Human | teneligliptin | 586 | 79.1% |
85068 | mitogen-activated protein kinase kinase 1 | Human | CH4987655 | 142 | 45.9% |
85069 | mitogen-activated protein kinase kinase 1 | Human | TAK-733 | 139 | 42.1% |
85089 | mitogen-activated protein kinase 14 | Human | pamapimod | 82 | 21.8% |
85230 | Retinoic acid receptor-γ | Human | trifarotene | 200 | 43.8% |
85248 | mitogen-activated protein kinase 1 | Human | compound 27 [PMID: 29775310] | 138 | 37.3% |
85267 | mitogen-activated protein kinase kinase kinase 12 | Human | GNE-3511 | 112 | 37.0% |
85268 | mitogen-activated protein kinase kinase kinase 12 | Human | compound 11 [PMID: 26431428] | 112 | 37.0% |
85282 | Janus kinase 2 | Human | tofacitinib | 140 | 47.8% |
85283 | Janus kinase 3 | Human | tofacitinib | 140 | 42.5% |
85284 | tyrosine kinase 2 | Human | tofacitinib | 139 | 43.5% |
85286 | Janus kinase 2 | Human | PF-04965842 | 139 | 46.3% |
85292 | Janus kinase 2 | Human | filgotinib | 140 | 47.8% |
85295 | Janus kinase 2 | Human | decernotinib | 139 | 46.9% |
85309 | Janus kinase 2 | Human | PF-06263276 | 143 | 47.7% |
85312 | Janus kinase 2 | Human | JNJ-7706621 | 140 | 48.1% |
85316 | IL2 inducible T cell kinase | Human | BMS-509744 | 132 | 49.2% |
85405 | Plasmodium falciparum dihydroorotate dehydrogenase | Plasmodium falciparum | DSM421 | 335 | 83.3% |
85410 | Plasmodium falciparum dihydroorotate dehydrogenase | Plasmodium falciparum 3D7 | DSM421 | 335 | 83.3% |
85411 | Plasmodium falciparum dihydroorotate dehydrogenase | Plasmodium falciparum 3D7 | DSM421 | 335 | 83.3% |
85569 | cyclin dependent kinase 2 | Human | RO3306 | 134 | 44.6% |
85570 | cyclin dependent kinase 2 | Human | RO3306 | 134 | 44.6% |
85576 | cyclin dependent kinase 2 | Human | SU9516 | 115 | 38.3% |
85577 | cyclin dependent kinase 2 | Human | SU9516 | 115 | 38.3% |
85589 | aurora kinase A | Human | JNJ-7706621 | 137 | 49.8% |
85793 | hydroxysteroid 11-beta dehydrogenase 1 | Human | BMS-823778 | 58 | 19.9% |
85807 | MAP kinase interacting serine/threonine kinase 2 | Human | tomivosertib | 137 | 43.0% |
85855 | Pim-1 proto-oncogene, serine/threonine kinase | Human | compound 28 [PMID: 30624936] | 138 | 47.9% |
85927 | Plasmodium falciparum proline--tRNA ligase | Plasmodium falciparum 3D7 | halofuginone | 176 | 34.6% |